Education
About Us
Working with TipRanks
Follow Us
ChromaDex Corporation (CDXC)
NASDAQ:CDXC
CDXC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.31 - $9.18
Previous CloseN/A
Volume55.16K
Average Volume (3M)N/A
Market Cap
$611.90M
Enterprise Value$254.35M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$2.65M
Price to Earnings (P/E)73.5
Beta0.57
Next Earnings
May 07, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding77,750,450
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)13.50
Price to Sales (P/S)6.20
P/FCF Ratio18.00
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue2.60
Enterprise Value/Gross Profit4.13
Enterprise Value/Ebitda28.73
Forecast
1Y Price Target
$9.03Price Target Upside16.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceChromaDex reported impressive earnings outperformance with multiple revenue accelerants.
Market ExpansionNiagen Plus products are now available at over 475 leading wellness clinics in the U.S., indicating a massive expansion.
Strategic RebrandingChromaDex announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new NASDAQ symbol 'NAGE', indicating a strategic rebranding effort.
Bears Say
Regulatory ChallengesIf the NO-PARK results prove positive, ChromaDex may explore the possibility of obtaining regulatory approval for a pharmaceutical-grade formulation of NR to treat Parkinson's disease.
Research And Development CostsThe company plans to continue investing in R&D to drive future innovation.
Sales And Marketing ExpensesSales and marketing expenses accounted for only 27.5% of net sales vs. 31% in the year-ago period.
Chromadex News
CDXC FAQ
What was ChromaDex Corporation’s price range in the past 12 months?
ChromaDex Corporation lowest stock price was $2.31 and its highest was $9.18 in the past 12 months.
What is ChromaDex Corporation’s market cap?
ChromaDex Corporation’s market cap is $611.90M.
When is ChromaDex Corporation’s upcoming earnings report date?
ChromaDex Corporation’s upcoming earnings report date is May 07, 2025 which is 92 days ago.
How were ChromaDex Corporation’s earnings last quarter?
Currently, no data Available
Is ChromaDex Corporation overvalued?
According to Wall Street analysts ChromaDex Corporation’s price is currently Undervalued.
Does ChromaDex Corporation pay dividends?
ChromaDex Corporation does not currently pay dividends.
What is ChromaDex Corporation’s EPS estimate?
ChromaDex Corporation’s EPS estimate is 0.02.
How many shares outstanding does ChromaDex Corporation have?
ChromaDex Corporation has 77,750,450 shares outstanding.
What happened to ChromaDex Corporation’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ChromaDex Corporation?
Currently, no hedge funds are holding shares in CDXC
Chromadex Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.03 (16.67% Upside)
$9.03 (16.67% Upside)
Blogger Sentiment
Bullish
CDXC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 26.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
22.94%
Trailing 12-Months
Asset Growth
24.22%
Trailing 12-Months
Company Description
ChromaDex Corporation
Chromadex Corp. is a nutraceutical company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Irvine, CA.
Chromadex (CDXC) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
CDXC Stock 12 Month Forecast
Average Price Target
$9.03
▲(16.67% Upside)
Ownership Overview
29.85% Insiders
6.99% Mutual Funds
7.48% Other Institutional Investors
48.77% Public Companies and
Individual Investors